Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating on Aktis Oncology (NASDAQ: AKTS) and has maintained a price target of $35 for the stock.